Arrowhead Pharmaceuticals heads into the final days of Q2 with shorts unwinding rapidly, options skewing heavily toward calls, and the Street largely constructive ahead of an August earnings catalyst.
The short side of the trade has compressed sharply this month. Short interest dropped 11% in a single week to around 7.9% of free float — and is down more than 20% from its May highs when roughly 13.5 million shares were borrowed. That's a meaningful retreat. Borrow costs are trivial at just 0.52% annually, and availability has ballooned to over 1,400% of outstanding short interest — roughly 83 million shares available against just under 11 million borrowed. The lending market is as open as it gets; there is no squeeze dynamic here. The ORTEX short score has followed the same trajectory, easing from 58 in late June to just above 51 now, placing ARWR in roughly neutral territory across the broader universe.
Options positioning reinforces the bullish drift. The put/call ratio has dropped to 0.36, nearly 1.5 standard deviations below its 20-day average of 0.49 — the lowest it has been in weeks. This week's PCR is running well under where it sat for most of June, when the ratio hovered between 0.55 and 0.57. The sharp rotation toward calls accelerated from June 22 onward, closely tracking the short interest unwind. Together, the two moves paint a consistent picture: bearish positioning is being dismantled, not rebuilt.
The analyst community is broadly aligned on the bull case, though conviction varies. JP Morgan initiated at Overweight in May with an $88 target, and Morgan Stanley upgraded to Overweight in April, lifting its target to $100. This week, HC Wainwright reiterated its Buy/$100 target and Chardan held at Buy/$90. The notable dissenter is Leerink Partners, which raised its target from $61 to $72 on June 17 but held at Market Perform — a signal that at least one firm sees the stock fairly valued near current levels. Bernstein sits similarly at Market Perform with a $46 target, well below the current $81.51 price, suggesting that the mean target of $89 obscures a real divergence between bulls at $87–$101 and more cautious names in the $46–$72 range. The bull case centers on Zodasiran's path toward ANGPTL3 approval and Arrowhead's breadth across cardiometabolic, neuromuscular, and pulmonary assets. The bear case focuses on competitive pressure in RNAi and prior weight-loss data disappointments that could resurface with fresh clinical readouts.
Insider activity has been one-sided in recent months, though the scale is modest. The CFO sold roughly $934,000 worth of shares across three transactions in late April. The CMO has been a consistent seller — three separate tranches between January and May totaling around $1.96 million. None of these carries high trade significance scores, and no buying has offset the flow over the 90-day window. The net 90-day insider position is a small positive in share terms, but that reflects earlier option exercises rather than open-market buying conviction. Among institutional holders, Vestal Point Capital stands out — the fund added 1.375 million shares in Q1, nearly doubling an existing stake to 2.275 million shares, a level of conviction that distinguishes it from the passive index flows dominating the top holder list.
The last earnings print offers useful context. On May 7, the stock fell 8.2% on the day, only to recover and close the following week roughly flat. That pattern — a sharp initial reaction absorbed over subsequent sessions — matters heading into the August 7 release. Correlated peers had a mixed week: MGTX rose 14.4% and IMNM gained 9.6%, while TSHA slipped 0.7% and IONS fell 1.7%. ARWR's 2% weekly gain sits comfortably in the middle of that range, neither leading nor lagging the cohort.
The next pivot is whether the short cover and call-side options rotation hold into the August 7 earnings release — and whether clinical pipeline updates between now and then sharpen or blunt the disagreement between bulls at $100 and bears still anchored well below the current price.
See the live data behind this article on ORTEX.
Open ARWR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
